1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. Financials
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  05/27 02:00:00 am EDT
3429.00 JPY   -0.46%
05:48aChugai Launches Vabysmo Intravitreal Injection 120 mg/mL for the Treatment of Age-related Macular Degeneration Associated with Subfoveal Choroidal Neovascularization and Diabetic Macular Edema
AQ
05/18Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued
AQ
04/28Chugai Pharmaceutical Co., Ltd. - Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 5 518 3599 045 9246 141 3115 665 211--
Enterprise Value (EV)1 5 185 3018 667 3045 669 3115 061 3344 896 0484 747 242
P/E ratio 35,0x42,1x20,3x16,8x18,4x17,7x
Yield 1,39%1,00%2,03%2,22%2,35%2,50%
Capitalization / Revenue 8,04x11,5x6,14x4,77x5,48x5,43x
EV / Revenue 7,56x11,0x5,67x4,26x4,74x4,55x
EV / EBITDA 22,5x26,1x12,3x10,1x10,8x10,2x
Price to Book 6,46x9,23x5,17x4,13x3,51x3,09x
Nbr of stocks (in thousands) 1 642 3691 643 8171 644 2601 644 473--
Reference price (JPY) 3 3605 5033 7353 5073 5073 507
Announcement Date 01/30/202002/04/202102/03/2022---
1 JPY in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 686 184786 900999 8001 186 8611 033 1211 043 023
EBITDA1 230 967332 600459 100501 555451 290464 976
Operating profit (EBIT)1 210 597301 200421 900473 846430 059447 702
Operating Margin 30,7%38,3%42,2%39,9%41,6%42,9%
Pre-Tax Profit (EBT)1 207 893298 200419 400475 896432 709450 768
Net income1 157 560214 700303 000342 603313 189325 989
Net margin 23,0%27,3%30,3%28,9%30,3%31,3%
EPS2 95,9131184208190198
Dividend per Share2 46,755,076,077,882,587,7
Announcement Date 01/30/202002/04/202102/03/2022---
1 JPY in Million
2 JPY
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3
Net sales1 287 264322 300360 554260 537558 508298 925
EBITDA ------
Operating profit (EBIT)1 122 156139 100187 00799 323244 708119 275
Operating Margin 42,5%43,2%51,9%38,1%43,8%39,9%
Pre-Tax Profit (EBT)1 119 689138 400186 20692 500244 858124 200
Net income1 86 01798 800131 77572 190183 50887 443
Net margin 29,9%30,7%36,5%27,7%32,9%29,3%
EPS2 52,360,180,145,414151,4
Dividend per Share ------
Announcement Date 10/22/202102/03/202204/25/2022---
1 JPY in Million
2 JPY
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 333 058378 620472 000603 877769 162917 969
Leverage (Debt / EBITDA) -1,44x-1,14x-1,03x-1,20x-1,70x-1,97x
Free Cash Flow1 124 900106 723160 699210 560334 903291 224
ROE (Net Profit / Equities) 19,6%23,4%28,0%26,6%21,1%19,3%
Shareholders' equity1 804 925917 5211 082 1431 290 0411 484 0021 685 168
ROA (Net Profit / Asset) 15,9%26,0%30,2%23,0%16,0%14,6%
Assets1 989 232826 0071 002 1581 487 3481 958 5092 233 873
Book Value Per Share2 5205967238501 0001 134
Cash Flow per Share2 108149203203228225
Capex1 53 00957 04065 96968 25468 49766 238
Capex / Sales 7,73%7,25%6,60%5,75%6,63%6,35%
Announcement Date 01/30/202002/04/202102/03/2022---
1 JPY in Million
2 JPY
Previous periodNext period
Estimates
Key data
Capitalization (JPY) 5 665 210 814 770
Capitalization (USD) 44 522 070 138
Net sales (JPY) 999 800 000 000
Net sales (USD) 7 857 283 194
Number of employees 7 664
Sales / Employee (JPY) 130 454 071
Sales / Employee (USD) 1 025 220
Free-Float 37,8%
Free-Float capitalization (JPY) 2 139 255 450 304
Free-Float capitalization (USD) 16 812 098 317
Avg. Exchange 20 sessions (JPY) 7 236 653 125
Avg. Exchange 20 sessions (USD) 56 871 807
Average Daily Capital Traded 0,1%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA